Abstracts tagged "Mortality"

Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…
Abstract Number: 1482 • ACR Convergence 2023
Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan
Takehiro Nakai¹, Sho Fukui², Takahiro Asano¹, Futoshi Iwata¹, Hiroki Ozawa³, Satoshi Kawaai¹, Yukihiko Ikeda⁴, Haruyuki Yanaoka¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁵, Kenichi YAMAGUCHI⁶ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Brigham and Women's Hospital, Boston, MA, ³Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁴St Luke's international hospital in Japan, Tokyo, Japan, ⁵Kyorin University School of Medicine, Yokohoma, Japan, ⁶St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…
Abstract Number: 1953 • ACR Convergence 2023
Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019
CLAUDIA MENDOZA PINTO¹, Pamela Munguía-Realpozo¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Paulina Cortés-Hernández¹, Roberto Arreguín-Reyes¹, Jorge Ayón-Aguilar¹ and Gabriel Rodríguez-Castillo², ¹Instituto Mexicano del Seguro Socia, Puebla, Mexico, ²Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Patients with polymyositis and dermatomyositis (PM/DM) present multiple complications that may lead to increased mortality rates and data on PM/DM mortality in Mexico is…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 1053 • ACR Convergence 2023
Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Denis Krutko¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵, Grant Cannon⁶ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…
Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Hamza Liaqat¹, Muhammad Qureshi², Awais Farooq³, Mashal Awais², Amar Patel⁴ and Aisha Barlas⁵, ¹Wah Medical College, Wah Cantt, Pakistan, ²Southeast Health Internal Medicine Residency Prog., Dothan, AL, ³University of Illinois Chicago, Chicago, IL, ⁴Texas Tech University Health Sciences Center, El paso, TX, ⁵Mercy Health, Rockford, IL
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…
Abstract Number: 1979 • ACR Convergence 2023
Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis
Jie Wei¹, david Hunter², Nancy Lane³, Jing Wu⁴, Chao Zeng⁵, Guanghua Lei⁵ and Yuqing Zhang⁶, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ³University of California, Hillsborough, CA, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: The current international guidelines recommend weight loss for pain relief and functional improvement in overweight or obese patients with knee or hip osteoarthritis; however,…
Abstract Number: 0299 • ACR Convergence 2023
Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)
Haseeb Chaudhary¹, Biraj Shrestha², Sarah Abi Doumeth³ and Maya Mattar⁴, ¹Case Western Reserve University, Westlake, OH, ²Tower Health System, Reading, PA, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH
Background/Purpose: Recent evidence suggests increased prevalence of venous thromboembolism (VTE) in patients with idiopathic inflammatory myopathies (IIM). The literature on the clinical implications of VTE…
Abstract Number: 1070 • ACR Convergence 2023
Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon
Julien Seiller¹, Emmanuel Massy², Julien Peron³ and Cyrille Confavreux², ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, Lyon, France, ²Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ³Service d’oncologie médicale. Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université de Lyon, INSERM U1290, Lyon, France
Background/Purpose: Since Immune Checkpoint Inhibitors (ICI) revolution, oncologists face immune-related adverse events (irAEs) including rheumatologic irAEs with inflammatory arthritis. Treatment of rheumatologic irAE can be…
Abstract Number: 1499 • ACR Convergence 2023
Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study
Saira Sheikh¹, James Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio R. Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes García¹¹, IGNACIO GARCÍA-DE LA TORRE¹², Sofia Fernandes¹³, Julia HN Harris¹⁴, Abhishek Roy¹⁵, Jose Miyar Olaiz¹⁶, Paul WIlde¹⁷ and David A. Roth¹⁸, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Service of Rheumatology of the Internal Medicine Department, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Medical University of South Carolina, Charleston, SC, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central; Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Universidad de Guadalajara/Hospital General de Occidente, Guadalajara, Mexico, ¹³GlaxoSmithKline, Stevenage, United Kingdom, ¹⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Bangalore, India, ¹⁶GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Collegeville, PA
Background/Purpose: Belimumab (BEL) is an approved treatment for active SLE and LN, in addition to standard therapy (ST). Despite BEL clinical studies demonstrating a favorable…
Abstract Number: 2115 • ACR Convergence 2023
Genetic Risk Load as a Predictor of Radiographic Damage and Mortality in Female Patients with Rheumatoid Arthritis
Jihye Kim¹, Yeon-Kyung Lee², Youngho Park³, Ayeong Kwon⁴, Young-Chang Kwon¹, Young Bin Joo², Hye-Soon Lee⁵, Kwangwoo Kim⁴, Sang-Cheol Bae⁶ and So-Young Bang², ¹Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Business Statistics, Hannam University, Daejeon, South Korea, ⁴Department of Biology, Kyung Hee University, Seoul, South Korea, ⁵Hanyang University, Guri, South Korea, ⁶Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by an unpredictable prognosis and increased mortality risk. Although the role of genetics in RA mortality…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 0284 • ACR Convergence 2022
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
Daniela Chicre¹, Alisson Pugliesi¹, Manoel Barros Bértolo¹, Vani de Abreu Souza Filho¹ and Luiz Sérgio F Carvalho², ¹Universidade Estadual de Campinas, Campinas, São Paulo, Brazil, ²Clarity: Inteligência em Saúde, Brasília, Brazil
Background/Purpose: The ORAL-Surveillance trial showed important data on the comparative safety between Tofacitinib and TNF inhibitors (TNFi) in the treatment of RA, leading to safety…
Abstract Number: 1378 • ACR Convergence 2022
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
Ha-Seul Jeoung¹, Kuan Liu¹, Roberta Berard², Wes Fidler³, Janet Pope⁴, Johannes Roth⁵, Carter Thorne⁶, Earl Silverman⁷ and Deborah Levy⁸, ¹University of Toronto, Toronto, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Ottawa, Ottawa, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…
Abstract Number: 2068 • ACR Convergence 2022
All-Cause Mortality in a Systemic Lupus Erythematosus Cohort
Michelle Petri¹, Joseph Levy², Urbano Sbarigia³ and Daniel W. Goldman¹, ¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johnson & Johnson, Beerse, Belgium
Background/Purpose: Multiple studies have documented that patients with SLE have a higher all-cause mortality. Active disease contributes to early deaths with later deaths more likely…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].